The Children’s Place Reports Fourth Quarter and Full Year 2023 Results
May 06, 2024 08:00 ET
|
The Children's Place, Inc.
SECAUCUS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- The Children’s Place, Inc. (Nasdaq: PLCE), an omni-channel children’s specialty portfolio of brands with an industry-leading digital-first model,...
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May 06, 2024 08:00 ET
|
Belite Bio, Inc
Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support...
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
May 06, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
May 06, 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
A Message to Our Valued Stakeholders - We're Here for the Long Haul
May 06, 2024 08:00 ET
|
Mobile-heath Network Solutions
SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today addresses the recent market...
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
May 06, 2024 08:00 ET
|
VYNE Therapeutics Inc.
In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic...
Safe & Green Holdings Corp Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
May 06, 2024 08:00 ET
|
Safe & Green Holdings Corp.
Miami, FL, May 06, 2024 (GLOBE NEWSWIRE) -- Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular...
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 06, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Enphase Energy Expands IQ8 Commercial Microinverter Deployments in North America
May 06, 2024 08:00 ET
|
Enphase Energy, Inc.
FREMONT, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery...
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 06, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo...